Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, will participate in the Leerink Partners Therapeutics Forum.
Management plans to host one-on-one investor meetings on July 15, 2026, in Boston.
Details
Market move: AVTX -3.56% in the Jul 7 session. conference participation
On Jul 7, the day this news came out, AVTX closed 3.56% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.
Data tracked by StockTitan Argus for the Jul 7 session.
Key Figures
- Conference date
- July 15, 2026
- Leerink Partners Therapeutics Forum in Boston
Historical Context
-
Added to Russell 2000 and 3000 indexes, boosting index investor exposure.
-
Added experienced biopharma executive to board following positive trial data.
-
Advanced AVTX-010 next-generation anti-IL-1β antibody toward IND filing.
-
Granted stock option inducement award to new employee under Nasdaq rule.
-
Reported Q1 2026 loss alongside financing and positive Phase 2 LOTUS data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.